Food-Grade Bacteria Expressing Elafin Protect Against Inflammation and Restore Colon Homeostasis

Treatment of Murine Colitis by Lactococcus lactis Secreting Interleukin-10

Steidler, L., Hans, W., Schotte, L., Neirynck, S., Obermeier, F., Falk, W., Fiers, W., & Remaut, E. (2000) · Science · doi:10.1126/science.289.5483.1352 · Cited by 1,513

A Phase I Trial With Transgenic Bacteria Expressing Interleukin-10 in Crohn’s Disease

Braat, H., Rottiers, P., Hommes, D. W., Huyghebaert, N., Remaut, E., Remon, J., van Deventer, S. J. H., Neirynck, S., Peppelenbosch, M. P., & Steidler, L. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.03.028 · Cited by 786

Regulatory interactions between CD45RBhigh and CD45RBlow CD4+ T cells are important for the balance between protective and pathogenic cell-mediated immunity.

Powrie, F., Correa-Oliveira, R., Mauze, S., & Coffman, R. L. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.2.589 · Cited by 613

Role for protease activity in visceral pain in irritable bowel syndrome

Cenac, N., Andrews, C. N., Holzhausen, M., Chapman, K., Cottrell, G., Andrade-Gordon, P., Steinhoff, M., Barbara, G., Beck, P., Bunnett, N. W., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29255 · Cited by 591 · cited 1×

Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10

Steidler, L., Neirynck, S., Huyghebaert, N., Snoeck, V., Vermeire, A., Goddeeris, B. M., Cox, E., Remon, J. P., & Remaut, E. (2003) · Nature Biotechnology · doi:10.1038/nbt840 · Cited by 545

Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence.

Wiedow, O., Schröder, J. M., Gregory, H., Young, J. A., & Christophers, E. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)77182-2 · Cited by 433

Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2.

Cénac, N., Coelho, A., Nguyen, C., Compton, S., Andrade-Gordon, P., MacNaughton, W., Wallace, J., Hollenberg, M., Bunnett, N., Garcia-Villar, R., et al. (2002) · American Journal of Pathology · doi:10.1016/s0002-9440(10)64466-5 · Cited by 386

Role of the microbiota in inflammatory bowel diseases

Nagalingam, N. A., & Lynch, S. V. (2012) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21866 · Cited by 315 · cited 1×

A Novel Mucosal Vaccine Based on Live Lactococci Expressing E7 Antigen and IL-12 Induces Systemic and Mucosal Immune Responses and Protects Mice against Human Papillomavirus Type 16-Induced Tumors

Bermúdez‐Humarán, L. G., Cortes‐Perez, N. G., Lefèvre, F., Guimarães, V., Rabot, S., Alcocer-González, J. M., Gratadoux, J., Rodrı́guez-Padilla, C., Taméz-Guerra, R. S., Corthier, G., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.11.7297 · Cited by 191

CLINICAL RELEVANCE OF PROTEINASE ACTIVATED RECEPTORS (PARS) IN THE GUT

Vergnolle, N. (2005) · Gut · doi:10.1136/gut.2004.048876 · Cited by 166

Next-generation probiotics: the spectrum from probiotics to live biotherapeutics

O’Toole, P. W., Marchesi, J. R., & Hill, C. (2017) · Nature Microbiology · doi:10.1038/nmicrobiol.2017.57 · Cited by 971

Principles of genetic circuit design

Brophy, J. A. N., & Voigt, C. A. (2014) · Nature Methods · doi:10.1038/nmeth.2926 · Cited by 965

Artificial-enzymes-armed Bifidobacterium longum probiotics for alleviating intestinal inflammation and microbiota dysbiosis

Cao, F., Jin, L., Gao, Y., Ding, Y., Wen, H., Qian, Z., Zhang, C., Hong, L., Huang, Y., Zhang, J., et al. (2023) · Nature Nanotechnology · doi:10.1038/s41565-023-01346-x · Cited by 491

Engineering bacteria for diagnostic and therapeutic applications

Riglar, D. T., & Silver, P. A. (2018) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.172 · Cited by 460

Microbiota dysbiosis and barrier dysfunction in inflammatory bowel disease and colorectal cancers: exploring a common ground hypothesis

Yu, L. C. (2018) · Journal of Biomedical Science · doi:10.1186/s12929-018-0483-8 · Cited by 419

Microbiota and metabolic diseases

Pascale, A., Marchesi, N., Marelli, C., Coppola, A., Luzi, L., Govoni, S., Giustina, A., & Gazzaruso, C. (2018) · Endocrine · doi:10.1007/s12020-018-1605-5 · Cited by 423

Dysbiosis in Inflammatory Bowel Disease: Pathogenic Role and Potential Therapeutic Targets

Santana, P. T., Rosas, S. L. B., Ribeiro, B. E., Marinho, Y., & de Souza, H. S. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073464 · Cited by 359

Microbiome therapeutics — Advances and challenges

Mimee, M., Citorik, R. J., & Lu, T. K. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.032 · Cited by 324

The commensal bacterium Faecalibacterium prausnitzii is protective in DNBS-induced chronic moderate and severe colitis models

Martín, R., Chain, F., Miquel, S., Lu, J., Gratadoux, J.-J., Sokol, H., Verdu, E. F., Bercik, P., Bermúdez-Humarán, L. G., & Langella, P. (2014) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000440815.76627.64 · Cited by 284

Role of commensal and probiotic bacteria in human health: a focus on inflammatory bowel disease

Martín, R., Miquel, S., Ulmer, J., Kechaou, N., Langella, P., & Bermúdez‐Humarán, L. G. (2013) · Microbial Cell Factories · doi:10.1186/1475-2859-12-71 · Cited by 285

Gut microbiota, host health, and polysaccharides

Xu, X., Xu, P., Ma, C., Tang, J., & Zhang, X. (2012) · Biotechnology Advances · doi:10.1016/j.biotechadv.2012.12.009 · Cited by 249

Emerging roles of the microbiome in cancer

Bultman, S. J. (2014) · Carcinogenesis · doi:10.1093/carcin/bgt392 · Cited by 239

Protease inhibition as new therapeutic strategy for GI diseases

Vergnolle, N. (2016) · Gut · doi:10.1136/gutjnl-2015-309147 · Cited by 226

Microbiota effects on cancer: From risks to therapies

Rea, D., Coppola, G., Palma, G., Barbieri, A., Luciano, A., Del Prete, P., Rossetti, S., Berretta, M., Facchini, G., Perdonà, S., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24681 · Cited by 208

Modulation of bone remodeling by the gut microbiota: A new therapy for osteoporosis

Lyu, Z., Hu, Y., Guo, Y., & Liu, D. (2023) · Bone Research · doi:10.1038/s41413-023-00264-x · Cited by 207

SuFEx-enabled, agnostic discovery of covalent inhibitors of human neutrophil elastase

Zheng, Q., Woehl, J. L., Kitamura, S., Santos‐Martins, D., Smedley, C. J., Li, G., Forli, S., Moses, J. E., Wolan, D. W., & Sharpless, K. B. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1909972116 · Cited by 205

Novel Fecal Biomarkers That Precede Clinical Diagnosis of Ulcerative Colitis

Galipeau, H. J., Caminero, A., Turpin, W., Bermudez-Brito, M., Santiago, A., Libertucci, J., Constante, M., Raygoza Garay, J. A., Rueda, G., Armstrong, S., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.12.004 · Cited by 190

The potential probiotic Lactobacillus rhamnosus CNCM I-3690 strain protects the intestinal barrier by stimulating both mucus production and cytoprotective response

Martín, R., Chamignon, C., Mhedbi-Hajri, N., Chain, F., Derrien, M., Escribano-Vázquez, U., Garault, P., Cotillard, A., Pham, H., Chervaux, C., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-41738-5 · Cited by 193

Protectin D1 n-3 DPA and resolvin D5 n-3 DPA are effectors of intestinal protection

Gobbetti, T., Dalli, J., Colas, R. A., Canova, D. F., Aursnes, M., Bonnet, D., Alric, L., Vergnolle, N., Deraison, C., Hansen, T. V., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617290114 · Cited by 176

Engineering lactococci and lactobacilli for human health

Bermúdez‐Humarán, L. G., Aubry, C., Motta, J., Deraison, C., Steidler, L., Vergnolle, N., Chatel, J., & Langella, P. (2013) · Current Opinion in Microbiology · doi:10.1016/j.mib.2013.06.002 · Cited by 164

Quantification and Potential Functions of Endogenous Agonists of Transient Receptor Potential Channels in Patients With Irritable Bowel Syndrome

Cénac, N., Bautzová, T., Faouder, P. L., Veldhuis, N. A., Poole, D. P., Rolland, C., Bertrand, J., Liedtke, W., Dubourdeau, M., Bertrand‐Michel, J., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.011 · Cited by 152

Microbiome therapeutics: exploring the present scenario and challenges

Yadav, M., & Chauhan, N. S. (2021) · Gastroenterology report · doi:10.1093/gastro/goab046 · Cited by 164

Lactic acid bacteria: reviewing the potential of a promising delivery live vector for biomedical purposes

Cano‐Garrido, O., Seras‐Franzoso, J., & García‐Fruitós, E. (2015) · Microbial Cell Factories · doi:10.1186/s12934-015-0313-6 · Cited by 148

Display of recombinant proteins at the surface of lactic acid bacteria: strategies and applications

Michon, C., Langella, P., Eijsink, V. G. H., Mathiesen, G., & Chatel, J. (2016) · Microbial Cell Factories · doi:10.1186/s12934-016-0468-9 · Cited by 147

The microbiome and its potential as a cancer preventive intervention

Bultman, S. J. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.001 · Cited by 134

Serine protease inhibitors protect better than IL-10 and TGF-β anti-inflammatory cytokines against mouse colitis when delivered by recombinant lactococci

Bermúdez‐Humarán, L. G., Motta, J., Aubry, C., Kharrat, P., Martin, L., Sallenave, J., Deraison, C., Vergnolle, N., & Langella, P. (2015) · Microbial Cell Factories · doi:10.1186/s12934-015-0198-4 · Cited by 128

Indoxyl sulfate induces intestinal barrier injury through IRF1-DRP1 axis-mediated mitophagy impairment

Huang, Y., Zhou, J., Wang, S., Xiong, J., Chen, Y., Liu, Y., Xiao, T., Li, Y., He, T., Li, Y., et al. (2020) · Theranostics · doi:10.7150/thno.45455 · Cited by 130

Epithelial expression and function of trypsin-3 in irritable bowel syndrome

Rolland-Fourcade, C., Denadai-Souza, A., Cirillo, C., Lopez, C., Jaramillo, J. O., Desormeaux, C., Cenac, N., Motta, J.-P., Larauche, M., Taché, Y., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-312094 · Cited by 126

Drinkable in situ-forming tough hydrogels for gastrointestinal therapeutics

Liu, G. W., Pickett, M. J., Kuosmanen, J. L. P., Ishida, K., Madani, W. A. M., White, G. N., Jenkins, J. A., Park, S., Feig, V. R., Jiménez, M., et al. (2024) · Nature Materials · doi:10.1038/s41563-024-01811-5 · Cited by 126

Gut microbiome and anticancer immune response: really hot Sh*t!

Viaud, S., Daillère, R., Boneca, I. G., Lepage, P., Langella, P., Chamaillard, M., Pittet, M. J., Ghiringhelli, F., Trinchieri, G., Goldszmid, R., et al. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.56 · Cited by 123

Development of a Stress-Inducible Controlled Expression (SICE) system in Lactococcus lactis for the production and delivery of therapeutic molecules at mucosal surfaces

Benbouziane, B., Ribelles, P., Aubry, C., Martín, R., Kharrat, P., Riazi, A., Langella, P., & Bermúdez‐Humarán, L. G. (2013) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2013.04.019 · Cited by 115

Lactic acid bacteria as mucosal delivery vehicles: a realistic therapeutic option

Wang, M., Gao, Z., Zhang, Y., & Pan, L. (2016) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-016-7557-x · Cited by 112

The gut microbiota at the intersection of bile acids and intestinal carcinogenesis: An old story, yet mesmerizing

Liu, T., Song, X., Khan, S., Li, Y., Guo, Z., Li, C., Wang, S., Dong, W., Liu, W., Wang, B., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32563 · Cited by 108

Gut microbial β-glucuronidases regulate host luminal proteases and are depleted in irritable bowel syndrome

Edwinson, A. L., Yang, L., Peters, S., Hanning, N., Jeraldo, P., Jagtap, P., Simpson, J. B., Yang, T.-Y., Kumar, P., Mehta, S., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01103-1 · Cited by 105

Endogenous Regulation of Visceral Pain via Production of Opioids by Colitogenic CD4+ T Cells in Mice

Boué, J., Basso, L., Cenac, N., Blanpied, C., Rolli–Derkinderen, M., Neunlist, M., Vergnolle, N., & Dietrich, G. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.09.020 · Cited by 104

Serine proteases as luminal mediators of intestinal barrier dysfunction and symptom severity in IBS

Edogawa, S., Edwinson, A. L., Peters, S. A., Chikkamenahalli, L. L., Sundt, W., Graves, S., Gurunathan, S. V., Breen-Lyles, M., Johnson, S., Dyer, R., et al. (2020) · Gut · doi:10.1136/gutjnl-2018-317416 · Cited by 101

Effects in the use of a genetically engineered strain of Lactococcus lactis delivering in situ IL-10 as a therapy to treat low-grade colon inflammation

Martín, R., Chain, F., Miquel, S., Natividad, J., Sokol, H., Verdú, E., Langella, P., & Bermúdez-Humarán, L. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.28549 · Cited by 88

Fecal Serine Protease Profiling in Inflammatory Bowel Diseases

Jablaoui, A., Kriaa, A., Mkaouar, H., Akermi, N., Soussou, S., Wysocka, M., Wołoszyn, D., Amouri, A., Gargouri, A., Maguin, E., et al. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00021 · Cited by 101

Oral delivery of bacteria: Basic principles and biomedical applications

Li, S., Jiang, W., Zheng, C., Shao, D., Liu, Y., Huang, S., Han, J., Ding, J., Tao, Y., & Li, M. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.09.011 · Cited by 95

Flavonoids as inhibitors of human neutrophil elastase

Jakimiuk, K., Gesek, J., Atanasov, A. G., & Tomczyk, M. (2021) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2021.1927006 · Cited by 102

Next generation probiotics for human health: An emerging perspective

Jan, T., Negi, R., Sharma, B., Kumar, S., Singh, S., Rai, A. K., Shreaz, S., Rustagi, S., Chaudhary, N., Kaur, T., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e35980 · Cited by 95

Engineering Diagnostic and Therapeutic Gut Bacteria

Landry, B. P., & Tabor, J. J. (2017) · Microbiology Spectrum · doi:10.1128/microbiolspec.bad-0020-2017 · Cited by 95

The potential of neutrophil elastase inhibitors as anti-inflammatory therapies

Henriksen, P. A. (2013) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000001 · Cited by 95

Light-Sensitive Lactococcus lactis for Microbe–Gut–Brain Axis Regulating via Upconversion Optogenetic Micro-Nano System

Pan, H., Sun, T., Cui, M., Ma, N., Yang, C., Liu, J., Pang, G., Liu, B., Li, L., Zhang, X., et al. (2022) · ACS Nano · doi:10.1021/acsnano.1c11536 · Cited by 93

The emerging roles of bacterial proteases in intestinal diseases

Caminero, A., Guzman, M., Libertucci, J., & Lomax, A. E. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2181922 · Cited by 92

Functional Proteomic Profiling of Secreted Serine Proteases in Health and Inflammatory Bowel Disease

Denadai-Souza, A., Bonnart, C., Tapias, N. S., Marcellin, M., Gilmore, B., Alric, L., Bonnet, D., Burlet-Schiltz, O., Hollenberg, M. D., Vergnolle, N., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-26282-y · Cited by 91

Mucosal targeting of therapeutic molecules using genetically modified lactic acid bacteria: an update

LeBlanc, J. G., Aubry, C., Cortes‐Perez, N. G., de LeBlanc, A. D. M., Vergnolle, N., Langella, P., Azevedo, V., Chatel, J., Miyoshi, A., & Bermúdez‐Humarán, L. G. (2013) · FEMS Microbiology Letters · doi:10.1111/1574-6968.12159 · Cited by 86

The Prospects for the Therapeutic Implications of Genetically Engineered Probiotics

Mazhar, S. F., Afzal, M., Almatroudi, A., Munir, S., Ashfaq, U. A., Rasool, M., Raza, H., Munir, H. M. W., Rajoka, M. S. R., & Khurshid, M. (2020) · Journal of Food Quality · doi:10.1155/2020/9676452 · Cited by 90

Engineering of lactic acid bacteria for delivery of therapeutic proteins and peptides

Plavec, T. V., & Berlec, A. (2019) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-019-09628-y · Cited by 86

Biotechnology of health-promoting bacteria

Douillard, F. P., & de Vos, W. M. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.03.008 · Cited by 98

Bacterially mediated drug delivery and therapeutics: Strategies and advancements

Wu, L., Bao, F., Li, L., Yin, X., & Hua, Z. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114363 · Cited by 80

Oral delivery of Lactococcus lactis that secretes bioactive heme oxygenase-1 alleviates development of acute colitis in mice

Shigemori, S., Watanabe, T., Kudoh, K., Ihara, M., Nigar, S., Yamamoto, Y., Suda, Y., Sato, T., Kitazawa, H., & Shimosato, T. (2015) · Microbial Cell Factories · doi:10.1186/s12934-015-0378-2 · Cited by 78

Recent advances in gut Microbiota mediated therapeutic targets in inflammatory bowel diseases: Emerging modalities for future pharmacological implications

Shamoon, M., Martin, N. M., & O'Brien, C. L. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104344 · Cited by 73

Novel Role of the Serine Protease Inhibitor Elafin in Gluten-Related Disorders

Galipeau, H. J., Wiepjes, M., Motta, J., Schulz, J. D., Jury, J., Natividad, J. M., Pinto-Sanchez, I., Sinclair, D., Rousset, P., Martín, R., et al. (2014) · The American Journal of Gastroenterology · doi:10.1038/ajg.2014.48 · Cited by 72

New therapeutic avenues in ulcerative colitis: thinking out of the box

Torres, J., Danese, S., & Colombel, J. (2013) · Gut · doi:10.1136/gutjnl-2012-303959 · Cited by 74

Emerging Frontiers in Microbiome Engineering

Inda, M. E., Broset, E., Lu, T. K., & de la Fuente‐Núñez, C. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.08.007 · Cited by 74

A Commensal Bifidobacterium longum Strain Prevents Gluten-Related Immunopathology in Mice through Expression of a Serine Protease Inhibitor

McCarville, J. L., Dong, J., Caminero, A., Bermudez-Brito, M., Jury, J., Murray, J. A., Duboux, S., Steinmann, M., Delley, M., Tangyu, M., et al. (2017) · Applied and Environmental Microbiology · doi:10.1128/aem.01323-17 · Cited by 71

Pharmacological approaches in celiac disease

McCarville, J. L., Caminero, A., & Verdu, E. F. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.09.002 · Cited by 68

Giardia co-infection promotes the secretion of antimicrobial peptides beta-defensin 2 and trefoil factor 3 and attenuates attaching and effacing bacteria-induced intestinal disease

Mańko, A., Motta, J., Cotton, J. A., Feener, T. D., Oyeyemi, A., Vallance, B. A., Wallace, J. L., & Buret, A. G. (2017) · PLoS ONE · doi:10.1371/journal.pone.0178647 · Cited by 69

Bacterial interference with canonical NFκB signalling

Johannessen, M., Askarian, F., Sangvik, M., & Sollid, J. E. (2013) · Microbiology · doi:10.1099/mic.0.069369-0 · Cited by 66

Faecal neutrophil elastase-antiprotease balance reflects colitis severity

Barry, R. E., Ruano‐Gallego, D., Radhakrishnan, S. T., Lovell, S., Yu, L., Kotik, O., Glegola-Madejska, I., Tate, E. W., Choudhary, J. S., Williams, H. R. T., et al. (2019) · Mucosal Immunology · doi:10.1038/s41385-019-0235-4 · Cited by 65

Active thrombin produced by the intestinal epithelium controls mucosal biofilms

Motta, J., Denadai‐Souza, A., Sagnat, D., Guiraud, L., Edir, A., Bonnart, C., Sebbag, M., Rousset, P., Lapeyre, A., Séguy, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11140-w · Cited by 63

Neutrophil Elastase Causes Tissue Damage That Decreases Host Tolerance to Lung Infection with Burkholderia Species

Sahoo, M., del Barrio, L., Miller, M. A., & Re, F. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004327 · Cited by 62

The Contribution of Gut Barrier Changes to Multiple Sclerosis Pathophysiology

Buscarinu, M. C., Fornasiero, A., Romano, S., Ferraldeschi, M., Mechelli, R., Reniè, R., Morena, E., Romano, C., Pellicciari, G., Landi, A. C., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01916 · Cited by 68

Immunomodulatory Effects of Lactobacillus Strains: Emphasis On Their Effects on Cancer Cells

Do, A. A., Taherian‐Esfahani, Z., Ghafouri‐Fard, S., Ghafouri-Fard, S., & Motevaseli, E. (2015) · Immunotherapy · doi:10.2217/imt.15.92 · Cited by 60

Synthetic Biology and the Gut Microbiome

Dou, J., & Bennett, M. R. (2017) · Biotechnology Journal · doi:10.1002/biot.201700159 · Cited by 59

Understanding Host-Adherent-InvasiveEscherichia coliInteraction in Crohn’s Disease: Opening Up New Therapeutic Strategies

Agus, A., Massier, S., Darfeuille–Michaud, A., Billard, E., & Barnich, N. (2014) · BioMed Research International · doi:10.1155/2014/567929 · Cited by 78

Interleukin-8 in gastrointestinal inflammation and malignancy: induction and clinical consequences

Beck, P. L., Cotton, J. A., Platnich, J. M., Muruve, D. A., Buret, A. G., & Jijon, H. B. (2016) · International Journal of Interferon Cytokine and Mediator Research · doi:10.2147/ijicmr.s63682 · Cited by 65

Synthetic Biology Approaches in the Development of Engineered Therapeutic Microbes

Kang, M., Choe, D., Kim, K., Cho, B., & Cho, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228744 · Cited by 61

Exploring the potential impact of probiotic use on drug metabolism and efficacy

Purdel, C. N., Ungurianu, A., Adam-Dima, I., & Margina, D. M. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114468 · Cited by 66

Probiotic Escherichia coli Nissle 1917 Expressing Elafin Protects Against Inflammation and Restores the Gut Microbiota

Teng, G., Li, H., Liu, Y., Wu, T., Dai, Y., Wang, H., & Wang, W. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.819336 · Cited by 56

Using murine colitis models to analyze probiotics–host interactions

Martín, R., Chain, F., Miquel, S., Motta, J., Vergnolle, N., Sokol, H., & Langella, P. (2017) · FEMS Microbiology Reviews · doi:10.1093/femsre/fux035 · Cited by 56

Applications of Genetically Modified Immunobiotics with High Immunoregulatory Capacity for Treatment of Inflammatory Bowel Diseases

Shigemori, S., & Shimosato, T. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00022 · Cited by 53

Understanding and Modulating Mammalian-Microbial Communication for Improved Human Health

Mani, S., Boelsterli, U. A., & Redinbo, M. R. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-140007 · Cited by 48

Use of genetically modified lactic acid bacteria and bifidobacteria as live delivery vectors for human and animal health

Levit, R., Cortes‐Perez, N. G., de LeBlanc, A. D. M., Loiseau, J., Aucouturier, A., Langella, P., LeBlanc, J. G., & Bermúdez‐Humarán, L. G. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2110821 · Cited by 49

Probiotics and Antibiotics in IBD

Sokol, H. (2014) · Digestive Diseases · doi:10.1159/000367820 · Cited by 48

Diversity oriented clicking delivers β-substituted alkenyl sulfonyl fluorides as covalent human neutrophil elastase inhibitors

Cheng, Y., Li, G., Smedley, C. J., Giel, M., Kitamura, S., Woehl, J. L., Bianco, G., Forli, S., Homer, J. A., Cappiello, J. R., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2208540119 · Cited by 46

A red light-controlled probiotic bio-system for in-situ gut-brain axis regulation

Zhang, X., Pang, G., Sun, T., Liu, X., Pan, H., Zhang, Y., Liu, J., Chang, J. K., Wang, H., & Liu, D. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122005 · Cited by 47

Advances in understanding of Netherton syndrome and therapeutic implications

Petrova, E., & Hovnanian, A. (2020) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2020.1857724 · Cited by 47

Human Neutrophil Elastase Proteolytic Activity in Ulcerative Colitis Favors the Loss of Function of Therapeutic Monoclonal Antibodies

Curciarello, R., Sobande, T. O., Jones, S., Giuffrida, P., Sabatino, A. D., Docena, G. H., MacDonald, T. T., & Kok, K. B. (2020) · Journal of Inflammation Research · doi:10.2147/jir.s234710 · Cited by 45

Siropins, novel serine protease inhibitors from gut microbiota acting on human proteases involved in inflammatory bowel diseases

Mkaouar, H., Akermi, N., Mariaule, V., Boudebbouze, S., Gaci, N., Szukala, F., Pons, N., Marquez, J., Gargouri, A. F., Maguin, E., et al. (2016) · Microbial Cell Factories · doi:10.1186/s12934-016-0596-2 · Cited by 43

Proteases and small intestinal barrier function in health and disease

Giuffrida, P., Biancheri, P., & MacDonald, T. T. (2014) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000042 · Cited by 43

Human airway trypsin-like protease, a serine protease involved in respiratory diseases

Menou, A., Duitman, J., Flajolet, P., Sallenave, J., Mailleux, A., & Crestani, B. (2017) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00509.2016 · Cited by 42

Recombinant Lactococcus lactis can make the difference in antigen-specific immune tolerance induction, the Type 1 Diabetes case

Robert, S., & Steidler, L. (2014) · Microbial Cell Factories · doi:10.1186/1475-2859-13-s1-s11 · Cited by 43

The serine protease inhibitor elafin maintains normal growth control by opposing the mitogenic effects of neutrophil elastase

Caruso, J. A., Akli, S., Pageon, L. R., Hunt, K. K., & Keyomarsi, K. (2014) · Oncogene · doi:10.1038/onc.2014.284 · Cited by 41

Epithelial production of elastase is increased in inflammatory bowel disease and causes mucosal inflammation

Motta, J.-P., Rolland, C., Edir, A., Florence, A.-C., Sagnat, D., Bonnart, C., Rousset, P., Guiraud, L., Quaranta-Nicaise, M., Mas, E., et al. (2021) · Mucosal Immunology · doi:10.1038/s41385-021-00375-w · Cited by 40

Digestive Inflammation: Role of Proteolytic Dysregulation

Mariaule, V., Kriaa, A., Soussou, S., Rhimi, S., Boudaya, H., Hernandez, J. L., Maguin, E., Lesner, A., & Rhimi, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062817 · Cited by 40

Probiotics

Mizock, B. A. (2015) · Disease-a-Month · doi:10.1016/j.disamonth.2015.03.011 · Cited by 42

Colitis Linked to Endoplasmic Reticulum Stress Induces Trypsin Activity Affecting Epithelial Functions

Tapias, N. S., Denadai‐Souza, A., Rolland-Fourcade, C., Quaranta, M., Blanpied, C., Marcellin, M., Edir, A., Rolland, C., Cirillo, C., Dietrich, G., et al. (2021) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjab035 · Cited by 43

Complementary and Alternative Medicine Strategies for Therapeutic Gut Microbiota Modulation in Inflammatory Bowel Disease and their Next-Generation Approaches

Basson, A. R., Lam, M. C., & Cominelli, F. (2017) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2017.08.002 · Cited by 38

Serine proteases at the cutting edge of IBD: Focus on gastrointestinal inflammation

Kriaa, A., Jablaoui, A., Mkaouar, H., Akermi, N., Maguin, E., & Rhimi, M. (2020) · The FASEB Journal · doi:10.1096/fj.202000031rr · Cited by 38

The Interplay Between Genetic Risk Factors and Proteolytic Dysregulation in the Pathophysiology of Inflammatory Bowel Disease

Tapias, N. S., Vergnolle, N., Denadai‐Souza, A., & Barreau, F. (2020) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjaa033 · Cited by 40

Sonogenetics-controlled synthetic designer cells for cancer therapy in tumor mouse models

Gao, T., Niu, L., Wu, X., Dai, D., Zhou, Y., Liu, M., Wu, K., Yu, Y., Guan, N., & Ye, H. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101513 · Cited by 39

Increased Mucosal Thrombin is Associated with Crohn’s Disease and Causes Inflammatory Damage through Protease-activated Receptors Activation

Motta, J., Palese, S., Giorgio, C., Chapman, K., Denadai‐Souza, A., Rousset, P., Sagnat, D., Guiraud, L., Edir, A., Séguy, C., et al. (2020) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjaa229 · Cited by 36

Mobilization of CD4+ T lymphocytes in inflamed mucosa reduces pain in colitis mice: toward a vaccinal strategy to alleviate inflammatory visceral pain

Basso, L., Boué, J., Augé, C., Deraison, C., Blanpied, C., Cénac, N., Lluel, P., Vergnolle, N., & Dietrich, G. (2017) · Pain · doi:10.1097/j.pain.0000000000001103 · Cited by 35

The Microbiome as a Therapeutic Target for Multiple Sclerosis: Can Genetically Engineered Probiotics Treat the Disease?

Kohl, H. M., Castillo, A., & Ochoa‐Repáraz, J. (2020) · Diseases · doi:10.3390/diseases8030033 · Cited by 36

Thrombin modifies growth, proliferation and apoptosis of human colon organoids: a protease‐activated receptor 1‐ and protease‐activated receptor 4‐dependent mechanism

Sébert, M., Denadai‐Souza, A., Quaranta, M., Racaud‐Sultan, C., Chabot, S., Lluel, P., Monjotin, N., Alric, L., Portier, G., Kirzin, S., et al. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14430 · Cited by 34

A New Bifidobacteria Expression SysTem (BEST) to Produce and Deliver Interleukin-10 in Bifidobacterium bifidum

Mauras, A., Chain, F., Faucheux, A., Ruffié, P., Gontier, S., Ryffel, B., Butel, M., Langella, P., Bermúdez‐Humarán, L. G., & Waligora‐Dupriet, A. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.03075 · Cited by 34

The intestinal microbiome and surgical disease

Krezalek, M. A., Skowron, K. B., Guyton, K. L., Shakhsheer, B. A., Hyoju, S. K., & Alverdy, J. C. (2016) · Current Problems in Surgery · doi:10.1067/j.cpsurg.2016.06.001 · Cited by 35

Metabolic engineering of human gut microbiome: Recent developments and future perspectives

Li, P., Roos, S., Luo, H., Ji, B., & Nielsen, J. (2023) · Metabolic Engineering · doi:10.1016/j.ymben.2023.06.006 · Cited by 34

Elafin—a potential IBD therapy

Greenhill, C. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.223 · Cited by 7

A gardian of gut epithelial barrier from inflammation: the elastase inhibitor ELAFIN

Deraison, C., Jaeger, M.-C., Guiraud, L., Rolland, C., Bellot, A., Rolland, C., Sebbag, M., Bermúdez‐Humarán, L. G., Langella, P., & Vergnolle, N. (2020) · The FASEB Journal · doi:10.1096/fasebj.2020.34.s1.05293

IBD's bacteria cafeteria

Lou, K.-J. (2012) · Science-Business eXchange · doi:10.1038/scibx.2012.1154

Probiotic Escherichia coli Nissle 1917 Expressing Elafin Protects Against Inflammation and Restores the Gut Microbiota

Teng, G., Li, H., Liu, Y., Wu, T., Dai, Y., Wang, H., & Wang, W. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.819336 · Cited by 56

Elafin-secreting lactic acid bacteria for treating inflammatory bowel disease (IBD)

(2012) · Science-Business eXchange · doi:10.1038/scibx.2012.1174 · Cited by 1